Can Fite Biopharma Ltd (NYSE American:CANF)
| 2.27 Delayed Data As of 3:29pm ET |  -0.11 / -4.62%Today’s Change | 1.52 Today|||52-Week Range 8.74 | -62.97% Year-to-Date |
Latest CANF News | Press Releases
| Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson Nov 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.38 |
| Today’s open | 2.38 |
| Day’s range | 2.27 - 2.40 |
| Volume | 57,898 |
| Average volume (3 months) | 62,851 |
| Market cap | $9.4M |
Data as of 3:29pm ET, 11/28/2023
Growth & Valuation
| Earnings growth (last year) | +54.82% |
| Earnings growth (this year) | +25.91% |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | -5.41% |
| P/E ratio | NM |
| Price/Sales | 20.66 |
| Price/Book | 1.26 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BNTCBenitec Biopharma In... | -0.12 | -3.77% |
| ONVOOrganovo Holdings In... | -0.01 | -0.85% |
| ---- | ||
| OTLCOncotelic Therapeuti... | -0.00 | -0.65% |
Data as of 3:59pm ET, 11/28/2023
Financials
| Last reporting date | November 28, 2023 |
| EPS forecast (this quarter) | -$0.53 |
| Annual revenue (last year) | $806.8K |
| Annual profit (last year) | -$10.1M |
| Net profit margin | -1,255.93% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Petach Tikva, Hamerkaz |
Forecasts
